膦甲酸
西多福韦
更昔洛韦
医学
伐更昔洛韦
巨细胞病毒
耐火材料(行星科学)
药理学
人巨细胞病毒
病毒学
病毒
病毒性疾病
疱疹病毒科
天体生物学
物理
出处
期刊:Drugs
[Springer Nature]
日期:2022-02-01
卷期号:82 (3): 335-340
被引量:24
标识
DOI:10.1007/s40265-022-01677-4
摘要
Maribavir (LIVTENCITYTM), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (≥ 12 years of age and weighing ≥ 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI